BGI SENTIS™ Comprehensive Hereditary Cancer Panel

Introduction

BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.

BGI’s Comprehensive Hereditary Cancer Panels provides information on 79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, pancreatic, prostate, and stomach cancer. BGI detects different alterations including germline SNV, Indels, and CNV.

  • SUITABLE FOR:

    Patients suspected of being at increased risk of hereditary cancer

  • TA TIME:

    14 - 26 days

  • SAMPLE:

    Peripheral blood, DNA, Saliva

  • TECHNOLOGY:

    Target region capture, High-throughput sequencing

List of Hereditary Cancers Panels

Why Choose BGI SENTIS™ Hereditary Cancer Screening?

  • Comprehensive – whole-exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements
  • Robust – Large gene rearrangements are verified by qPCR
  • Convenient – test from blood or saliva; DNA is also accepted
  • Professional – Professional database ensures up-to-date analysis and interpretation.
Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.

Workflow

Ordering the BGI SENTIS™ Hereditary Cancer Screening is easy.

  • STEP 1

    Physician orders test

  • STEP 2

    Blood or saliva sample collected

  • STEP 3

    Sample shipped to BGI and analyzed

  • STEP 4

    Results sent to physician

TOP